Evidence map›Paper›PMID 30519197›Full record

ReviewFrontiers in psychiatry2018

A Review of Risk Factors for Methamphetamine-Related Psychiatric Symptoms.

Xiangwen Chang, Yan Sun, Yang Zhang, Jiana Muhai, Lin Lu, Jie Shi

Abstract readReview
In one paragraph

Review in Frontiers in psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Methamphetamine dependence in Australia-why is 'ice' (crystal meth) so addictive?Psychiatry, psychology, and law : an interdisciplinary journal of the Australian and New Zealand Association of Psychiatry, Psychology and Law · 2024
    Article
  4. Article
  5. Astrocyte-derived TNF and glutamate critically modulate microglia activation by methamphetamine.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Article
  6. Article
  7. Aberrant expression ofGeneral psychiatry · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiangwen ChangNational Institute on Drug Dependence, Peking University, Beijing, China.
Yan SunNational Institute on Drug Dependence, Peking University, Beijing, China.
Yang ZhangNational Institute on Drug Dependence, Peking University, Beijing, China.
Jiana MuhaiNational Institute on Drug Dependence, Peking University, Beijing, China.
Lin LuNational Institute on Drug Dependence, Peking University, Beijing, China.
Jie ShiNational Institute on Drug Dependence, Peking University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The illegal use of methamphetamine (MA) is a growing public health concern globally and results in a series of negative effects. The prominent detrimental effect of MA use is MA-related psychiatric symptoms (MAP) and is observed at a much higher incidence compared to the general population. MAP often includes multiple dimensions of cognitive impairment and induces adverse consequences such as, violence and suicide. However, the assessment methods for MAP are not standardized. Hence, it is necessary to investigate factors that affect the progression of psychiatric symptoms in individuals who use MA. A review of published studies was performed by searching the following databases: PubMed, EMBASE, and PsycINFO from inception to 31 May, 2018. The search strategy included methamphetamine, dependence, psychiatric symptoms, and risk factor terms. We reviewed the different features of MAP and the various types of assessment instruments and summarized MAP risk factors from MA use-related factors, socio-demographic characteristics, life events, and genetic factors. We found that MAP was consistently and causally associated with MA use, particularly as it relates to the frequency and amount of MA use. Other MAP-related risk factors like life events and genetics were relatively inconsistent in their association with MAP. Hence, causal and longitudinal studies that focus on multilateral comparisons are required. This review provides high quality evidence for MAP risk factors and would be helpful for developing early prevention and treatment strategies for MAP.

Indexed as

assessment instrumentsgenetic factorsmethamphetamine (MA)methamphetamine-related psychiatric symptoms (MAP)methamphetamine use related factorsrisk factorssocio-demographic variables and life events

Identifiers

PMID30519197
PMCPMC6251327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.